In:
Cancer Research, American Association for Cancer Research (AACR), Vol. 71, No. 24_Supplement ( 2011-12-15), p. P3-07-42-P3-07-42
Abstract:
Background. Sentinel lymph node biopsy (SLNB) biopsy is routinely practised for axillary staging with 25–30% having positive SLN. Tumour size is the most important parameter taken into consideration in decision making in node negative patients with a size cut off for 4–5cm dependant on different units. Lymphovascular invasion (LVI) and Ki-67 a cell-cycle antigen are known important prognostic markers along with the tumour grade, oestrogen receptor and herceptin receptor status. Aim. To examine whether lymphovascular invasion, Ki-67 or any other factors can be used as a predictor for axillary lymph node involvement and hence prognosis. METHODS. A prospective study of 264 patients with invasive breast cancer undergoing SLN biopsy between January 2009 and December 2010. Histopathology reports were reviewed regarding LVI, Ki-67, grade, oestrogen, Progesterone and Herceptin receptor and SLN status. Stats direct was used to analyse data. Logistic regression was used and p-value calculated. RESULTS. LVI (p value=0.0001) and size(p value=0.0273) were the two most significant factors associated with node positivity. Grade of tumour had a p-value of 0.0825 and Ki67 had a p-value of 0.5217 which were not significant. DISCUSSION. LVI is the factor which best corelates with presence of metastasis in sentinel lymph node. If this information is available at the time of decision making, it should be strongly considered and pathologists should be encouraged to provide the information. In the absence of LVI, size still remains the best predictor of sentinel lymph node metastasis pre-operatively although consideration of other factors, such as the grade is definitely relevant. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P3-07-42.
Type of Medium:
Online Resource
ISSN:
0008-5472
,
1538-7445
DOI:
10.1158/0008-5472.SABCS11-P3-07-42
Language:
English
Publisher:
American Association for Cancer Research (AACR)
Publication Date:
2011
detail.hit.zdb_id:
2036785-5
detail.hit.zdb_id:
1432-1
detail.hit.zdb_id:
410466-3
Permalink